The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer

Hepatocyte growth factor/mesenchymal-epidermal transition factor (MET) dysregulation is a viable target in non-small cell lung cancer, both alone and potentially in combination with epidermal growth factor receptor inhibition. Future trials involving epidermal growth factor receptor and MET inhibitors should focus on more selected patient populations and include relevant biomarker studies. See referenced original article on pages 000-000, this issue.

http://ift.tt/2qwcGns